Delving into the Latest Updates on Filovirus vaccine (AlphaVax) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Filovirus (AlphaVax)

Target-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Filoviridae Infections

Inactive Indication-

Originator Organization

AlphaVax, Inc.

Active Organization

AlphaVax, Inc.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

AbstractNowadays, filovirus vaccine development may be seen as a paradigm for our response capabilities to emerging and re-emerging infectious diseases. Specifically, the West African Ebola virus disease (EVD) epidemic accelerated countermeasure licensure for several vaccine and therapeutic products. Those products have been successfully used to control EVD outbreaks in Central Africa over the past years. This positive development, however, has not yet reached beyond EVD. Therefore, it is pertinent to increase our efforts in the development of countermeasures for other human pathogenic members of the family Filoviridae as they continue to threaten public health in Sub-Saharan Africa. This review article summarizes the current filovirus vaccines in preclinical macaque studies and human clinical trials and discusses the most promising recent advancements.

100 Deals associated with Filovirus vaccine (AlphaVax)

Login to view more data